secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2026-09-04T20:06:30+00:00
Accession:  0001193125-26-383645
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia secures $400M non-dilutive credit facility with OrbiMed; $75M funded upfront
--------------------------------------------------------------------------------

- $75M funded at closing; up to $325M additional tied to milestones (FDA approval of lonvo-z, revenue targets, equity raise, mutual agreement).
- Interest at SOFR + 6.15% (3% floor), maturity Sept 4, 2031; secured by substantially all assets incl. IP.
- Proceeds for working capital and general corporate purposes; covenants include maintaining $50M liquidity until FDA approval of lonvo-z.
- Facility provides flexibility for lonvo-z launch in HAE and pipeline advancement; TD Cowen advised Intellia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312526383645/0001193125-26-383645-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312526383645/d110798d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-383645

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer